- Trials with a EudraCT protocol (296)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
296 result(s) found for: Screen time.
Displaying page 15 of 15.
EudraCT Number: 2018-001718-13 | Sponsor Protocol Number: MP18 | Start Date*: 2019-10-18 |
Sponsor Name:MAPS Europe B.V. | ||
Full Title: An Open- Label, Phase 2, Multicenter Feasibility Study if Manualized MDMA-Assisted Psychotherapy with an fMRI sub-study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Dis... | ||
Medical condition: post-traumatic stress disorder (PTSD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) CZ (Completed) NO (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-001447-12 | Sponsor Protocol Number: 331-10-234 | Start Date*: 2019-01-11 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo- and Active controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 years old) With Schizophr... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Ongoing) PL (Completed) BG (Prematurely Ended) FR (Ongoing) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003728-64 | Sponsor Protocol Number: E2027-G000-201 | Start Date*: 2018-12-03 | |||||||||||
Sponsor Name:Eisai Ltd | |||||||||||||
Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies | |||||||||||||
Medical condition: Dementia With Lewy Bodies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004086-87 | Sponsor Protocol Number: HZA107116 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A randomized, double-blind, parallel group, multicenter, stratified, study evaluating the efficacy and safety of once daily fluticasone furoate/vilanterol inhalation powder compared to once daily f... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) IT (Completed) PL (Completed) Outside EU/EEA LT (Completed) HU (Completed) BG (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004656-14 | Sponsor Protocol Number: BGB-A317-A1217-301 | Start Date*: 2021-11-02 | |||||||||||
Sponsor Name:BeiGene, Ltd. | |||||||||||||
Full Title: Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiotherapy (cCRT) Followed by Ociperlimab Plus Tislelizumab or Tislelizu... | |||||||||||||
Medical condition: Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Prematurely Ended) NL (Completed) PL (Completed) ES (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003237-41 | Sponsor Protocol Number: MK-7339-012 | Start Date*: 2020-06-23 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by ... | |||||||||||||
Medical condition: unresectable, locally advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) HU (Trial now transitioned) LV (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) EE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) RO (Trial now transitioned) IT (Trial now transitioned) LT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-006067-28 | Sponsor Protocol Number: CST103/CST107-CLIN-011 | Start Date*: 2022-01-10 | ||||||||||||||||||||||||||
Sponsor Name:CuraSen Therapeutics, Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 co-administered with CST-107 on the Central Nervous System in Subjects with Neur... | ||||||||||||||||||||||||||||
Medical condition: Patients with Parkinson’s Disease with REM sleep behaviour disorder, Mild Cognitive Impairment, Dementia with Lewy Bodies and Parkinson’s Disease Dementia. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-010269-21 | Sponsor Protocol Number: ING112276 | Start Date*: 2009-06-24 | |||||||||||
Sponsor Name:ViiV Healthcare UK Ltd | |||||||||||||
Full Title: A Phase IIb study to select a once daily oral dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naïve adult subjects. | |||||||||||||
Medical condition: HIV-1 infected antiretroviral therapy naïve adult subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023600-27 | Sponsor Protocol Number: FpS-AS-201 | Start Date*: 2012-01-11 |
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||
Full Title: A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Su... | ||
Medical condition: Persistent Asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) HU (Completed) BG (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001773-17 | Sponsor Protocol Number: FGCL-4592-082 | Start Date*: 2017-11-06 |
Sponsor Name:FibroGen, Inc. | ||
Full Title: A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome... | ||
Medical condition: Anemia due to Myelodysplastic Syndrome (MDS) in International Prognostic Scoring System – Revised Very Low, Low, or Intermediate Risk with <5% Blasts, and has low red blood cell transfusion burden ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) BE (Completed) DK (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-002722-22 | Sponsor Protocol Number: H2020/755094/2017/IT-01 | Start Date*: 2019-06-03 | |||||||||||
Sponsor Name:Humanitas Mirasole SpA | |||||||||||||
Full Title: Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS) | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001635-23 | Sponsor Protocol Number: TMC114IFD3003 | Start Date*: 2012-01-17 | |||||||||||
Sponsor Name:Janssen Cilag International N.V. | |||||||||||||
Full Title: PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) IE (Completed) DE (Completed) ES (Completed) AT (Completed) HU (Completed) DK (Completed) IT (Completed) SE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020983-39 | Sponsor Protocol Number: ING114467 | Start Date*: 2010-12-30 | |||||||||||
Sponsor Name:ViiV Healthcare UK Limited | |||||||||||||
Full Title: A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks ... | |||||||||||||
Medical condition: HIV-1 infected antiretroviral therapy naive adult subjects. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) ES (Completed) GB (Completed) HU (Completed) DK (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002138-35 | Sponsor Protocol Number: CLGX818X2103 | Start Date*: 2012-11-07 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: A phase Ib/II multi-center, open-label, dose escalation study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in patients with BRAF mutant metastatic colorectal cancer | |||||||||||||
Medical condition: BRAF mutant metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) NL (Completed) IT (Completed) NO (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000783-25 | Sponsor Protocol Number: 0518-032 | Start Date*: 2007-05-23 | |||||||||||
Sponsor Name:Merck Sharp & Dohme de España, S.A. | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected Patients Switched from a Stable KALE... | |||||||||||||
Medical condition: HIV Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003974-29 | Sponsor Protocol Number: D6186C00001 | Start Date*: 2019-08-15 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy | |||||||||||||
Medical condition: Advanced Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) DK (Completed) ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
